AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, & Head of Development starting Aug 2025.

New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north ...

Eight New Jersey-based companies have earned spots on U.S. News & World Report’s 2024 list of “Best Companies to Work For." ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

This was the stock's second consecutive day of losses.

Bristol Myers Squibb has raided AstraZeneca to find its next chief medical officer (CMO), persuading Cristian Massacesi, M.D.

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development.